Termination by Biogen. Biogen, in its sole discretion, shall have the right to terminate with immediate effect the conduct of the Trial at any time and give notice to the Institution and the Investigator accordingly. Upon receipt of the notice to terminate the Trial, the Institution and the Investigator shall immediately take all reasonable steps to cease conduct of the Trial at the Institution as soon as reasonably possible and to protect the welfare of Subjects participating in the Trial.
Termination by Biogen. BIOGEN may terminate this Agreement, and the --------------------- rights and obligations hereunder, or may remove any Licensed Clone and the licenses related thereto from operation of this Agreement, in its sole discretion at any time by giving written notice thereof to CURAGEN. Such termination shall be effective fifteen (15) days following the date such notice is received by CURAGEN and shall have all consequences as set forth in Section 6.2 above, but only with respect to the specified Licensed Clone(s), as if this Agreement had been terminated pursuant to Section 6.1(a).
Termination by Biogen. 33 (ii) 10.3 Termination for Breach..........................................33 10.4 Consequences of Termination.....................................33 10.5 Survival of Rights and Obligations..............................33 Article 11. Miscellaneous..................................................34
Termination by Biogen. Biogen may terminate this Agreement at any time for any reason upon written notice to Ontogeny. This Agreement shall be deemed to have been terminated by Biogen (i) in the event Biogen does not initiate at least one Development Program on or prior to July 1, 2000 or (ii) the termination by Biogen of the Commercialization Phase pursuant to Section 2.2(e)(ii).
Termination by Biogen. Biogen, in its sole discretion, shall have the right to terminate with immediate effect the conduct of the Trial at any time and give notice to the Institution and the Investigator accordingly. Upon receipt of the notice to terminate the Trial, the Institution and the Investigator shall immediately take all reasonable steps to cease conduct of the Trial at the Institution as soon as reasonably possible and to protect the welfare of Subjects participating in the Trial.
(c) Ukončení smlouvy ze strany Zdravotnického zařízení. Zdravotnické zařízení má právo ukončit provádění Klinického hodnocení, pokud je to nutné k ochraně zdraví Subjektů.
Termination by Biogen. If this Agreement is terminated by Biogen pursuant to Section 10.2, the licenses and option granted under this Agreement shall terminate, provided, however, that (i) Ontogeny shall retain any licenses granted to Ontogeny by Biogen pursuant to Section 3.2 or Section 3.3, subject to payment of the applicable royalty or other consideration, if any, set forth in this Agreement and (ii) Biogen shall retain the license granted to Biogen by Ontogeny pursuant to Section 3.3(a), subject to payment of the applicable royalty or other consideration, if any, set forth in this Agreement.
Termination by Biogen. Biogen may terminate the Research Program, at its sole discretion at any time, upon 60 days’ prior written notice to Catalyst. In the event of such a termination, Catalyst shall wind-down any on-going Catalyst Research Activities in an expeditious manner and not commence any new Catalyst Research Activities following its receipt of the termination notice. Biogen will reimburse Catalyst in accordance with Section 7.2 (Reimbursement of Research Costs) for any [***]. Catalyst will use commercially reasonable efforts to mitigate such costs.
Termination by Biogen. Biogen may terminate this Agreement upon written notice to Samsung if and only if:
a. The Closing does not occur by March 31, 2012; provided, however, that Biogen may terminate this Agreement pursuant to this Section 17.2(a) only if the Closing has not occurred by such date for a reason other than Biogen’s failure to fulfill any of its obligations under this Agreement, which failure has been the cause of or has resulted in the failure of the Closing to occur on or before such date;
b. Samsung commits a material breach of any of its representations, warranties, covenants or obligations under this Agreement and fails to cure such breach within thirty (30) days after receipt of written notice from Biogen specifying the particulars of such breach and requiring such breach to be remedied; or
c. Samsung, any of its creditors or any other eligible party files or commences a proceeding for the liquidation, bankruptcy, receivership, reorganization, rehabilitation, composition or dissolution of Samsung (and, in the case of any such proceeding brought against Samsung, such proceeding has not been stayed or dismissed within ninety (90) days after the filing thereof), or Samsung is unable to pay or has suspended payment of its debts generally as they become due (except debts being contested in good faith), or the creditors of Samsung have taken over its management, or the relevant financial institutions have suspended the clearing house privileges of Samsung.
Termination by Biogen. Biogen, in its sole discretion, shall have the right to terminate with immediate effect the conduct of the Trial at any time and give notice to the Institution (b) Ukončení smlouvy ze strany společnosti Biogen. Biogen má právo kdykoliv dle vlastního uvážení ukončit s okamžitou účinností Klinické hodnocení a toto oznámit and the Investigator accordingly. Upon receipt of the notice to terminate the Trial, the Institution and the Investigator shall immediately take all reasonable steps to cease conduct of the Trial at the Institution as soon as reasonably possible and to protect the welfare of Subjects participating in the Trial. The expected term of the Trial is by . Zdravotnickému zařízení a Zkoušejícímu. Poté, co Zdravotnické zařízení a Zkoušející obdrží oznámení o ukončení Klinického hodnocení, podniknou s okamžitou účinností veškeré přiměřené kroky k zastavení Klinického hodnocení v nejbližším možném termínu a k ochraně zdraví Subjektů účastnících se Klinického hodnocení. Předpokládaný termín řádného ukončení Klinického hodnocení je .
Termination by Biogen. Idec Under Sections 12.2(c) or 12.2(d). If this Agreement is terminated by Biogen Idec under Sections 12.2(c) or 12.2(d), then:
(i) all licenses granted by Biogen Idec to PTI will terminate;
(ii) all licenses granted by PTI to Biogen Idec will survive such termination;
(iii) All co-Development and co-Commercialization will cease, all Co-Development Compounds will become Sole Development Compounds, and all Co-Developed CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Licensed Products and Co-Commercialized Licensed Products will become Sole Licensed Products. PTI will reasonably assist Biogen Idec, for a period of no more than [***], in transferring to Biogen Idec all materials and information necessary for Biogen Idec to continue the research, Development and Commercialization of all Licensed Products; and
(iv) Biogen Idec will be released from the exclusivity restrictions set forth in Section 7.7 and will be free to research, Develop and Commercialize products that modulate the Target either by itself or with collaborators; provided that Biogen Idec continues to use Commercially Reasonable Efforts to Develop and Commercialize all such Licensed Products and pay all amounts due to PTI hereunder during the Term that would otherwise be payable; provided further that the royalty rates payable by Biogen Idec to PTI will be reduced by [***] from the rates set forth in Section 6.5.
